TXMD:NASDAQTherapeuticsMD, Inc. Analysis

TherapeuticsMD, Inc. (TXMD) is trading at $2.03, just above the identified support level of $1.92, while the 20‑day SMA (2.09) sits slightly above the 50‑day SMA (2.15), suggesting a neutral short‑term trend. The RSI of 44 points to neither overbought nor oversold conditions, but the MACD histogram remains negative, indicating lingering bearish momentum. Volatility is elevated at 56% over the past 30 days and the beta of 0.47 points to modest market sensitivity, yet the stock’s market cap of roughly $23 M and decreasing volume raise liquidity concerns. From a valuation perspective, the DCF‑derived fair value of $1.07 is well below the current price, flagging the stock as overvalued, and the forward PE of 5.8 is far beneath the industry average of 26.8, reflecting a price‑to‑earnings disconnect. Fundamental metrics are weak: operating margins are deeply negative, cash flow is modest, and the company carries a high debt‑to‑equity ratio of 22.7. Recent news offers no clear catalyst, merely noting mixed relative performance without material developments. Overall, the blend of technical neutrality, overvaluation, high volatility, and fragile fundamentals suggests caution.